Articles related to BONE HEALTH
Reduced Intensity Hematopoietic Stem Cell Transplantation for Accelerated-Phase Myelofibrosis
The authors analyzed the outcome of 349 patients with primary or secondary myelofibrosis undergoing reduced intensity transplantation, of whom 35 had accelerated-phase myelofibrosis. After a median follow-up of 5.9 years, estimated 5-year overall survival was between the two groups, and median overall survival was not reached. In terms of relapse, five-year incidence was 30% for the accelerated-phase group versus 15% for the chronic-phase group. Reduced intensity transplantation showed excellent survival but higher relapse for accelerated-phase myelofibrosis.
Hematology March 8th 2022
Comparative Fracture Risk During Osteoporosis Drug Holidays After Long-Term Risedronate vs. Alendronate Therapy
A new study has found that people with osteoporosis may experience less protection and be subject to more bone fractures when treated with the drug risedronate. Patients who were treated with risedronate during a drug holiday experienced more hip and other fractures than patients given other medications. Drug holidays are recommended after three to five years on therapy for most people taking bisphosphonates for osteoporosis. Risedronate, with its shorter half-life compared with alendronate, is associated with a somewhat higher risk of hip fracture during a drug holiday.
Endocrinology, Diabetes, Metabolism January 19th 2022